ArticleClinical rheumatology2026
Tofacitinib versus BAFF inhibitor in mild to moderate systemic lupus erythematosus: a real-world study based on CSTAR cohort.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesCompare the efficacy of tofacitinib and BAFF inhibitor (belimumab and telitacicept) in mild to moderate systemic lupus erythematosus patients.
methodsOverall, 33 patients treated with tofacitinib and 34 patients treated with BAFF inhibitor (23 patients underwent belimumab and 11 patients underwent telitacicept) were enrolled in this study. The patients were evaluated at 1, 3, 6, and 12 months after the baseline. The primary endpoint was set as the proportion of patients who achieved British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response.
resultsAt 3 months, BICLA responses were achieved in 27 (81.8%) patients treated with tofacitinib and 18 (52.9%) individuals treated with BAFF inhibitor. The BICLA response rate of tofacitinib is significantly higher than that of BAFF inhibitor (p = 0.012). Meanwhile, there was no discernible difference between the patients in the tofacitinib-treated group and the BAFF inhibitor-treated group in terms of the 3-month arthritis resolution rate (p = 0.117) or the mucocutaneous resolution rate (p = 0.175). Only one patient reported adverse events in the TOFA group during the 1-year follow-up. No severe adverse events, including infections, thromboembolic events, or deaths, were reported in both groups.
conclusionCompared to BAFF inhibitors, tofacitinib showed the potential efficacy in individuals with mild to moderate SLE. The results paved the way to optimal utilization of tofacitinib in SLE patients. Key Points • BAFF inhibitor is recommended as first-/second-line therapy for mild to moderate SLE patients. • The rapid efficacy of tofacitinib in treating mucocutaneous involvement and arthritis in lupus has been demonstrated. • This study firstly compares tofacitinib with BAFF inhibitor in SLE patients, suggesting that tofacitinib can faster achieve promising therapeutic effects in mild to moderate SLE patients.
Indexed as
Identifiers
41979813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.